- Details
- Sam Chang hosts Yair Lotan to discuss non-coding RNA as a predictor of bladder cancer subtypes. Dr. Lotan describes a multicenter retrospective analysis of 230 cystectomy patients without neoadjuvant chemotherapy, focusing on identifying favorable subgroups within luminal tumors. His team found that specific non-coding RNA patterns within the luminal subtype correlate with less upstaging and bette...
|
- Details
- Sam Chang speaks with Amanda Nizam about research on real-world treatment-related toxicities in locally advanced and metastatic urothelial carcinoma. Dr. Nizam shares findings from a Flatiron database analysis of over 5,300 patients treated between 2016-2023, comparing six different treatment regimens including enfortumab vedotin plus pembrolizumab, single-agent immunotherapies, and platinum-based...
|
- Details
- Zachary Klaassen speaks with Srikala Sridhar about a publication comparing industry-sponsored trials (ISTs) and investigator-initiated trials (IITs) in advanced genitourinary cancers across the US, Canada, UK, and France. Dr. Sridhar shares findings from the analysis of nearly 6,000 trials between 2007-2021, highlighting that while distribution was initially balanced, ISTs have increasingly outpac...
|
- Details
- Ashish Kamat interviews Di Maria Jiang about antibody-drug conjugates (ADCs) in bladder cancer treatment. Dr. Jiang describes how ADCs have triggered a "golden era" in bladder cancer management, transforming the treatment landscape particularly as they expand into earlier disease stages. She discusses how EV-pembrolizumab has largely replaced platinum chemotherapy as first-line therapy for metasta...
|
- Details
- Leslie Ballas interviews Elizabeth Guancial about gender differences in bladder cancer presentation and treatment. Dr. Guancial explains that women typically experience longer diagnostic delays than men, often receiving multiple antibiotic courses or gynecological workups before urological referral. She notes that once diagnosed, women tend to more thoroughly consider all treatment options, while...
|
- Details
- Ashish Kamat speaks with Bogdana Schmidt about the expanding landscape of non-muscle invasive bladder cancer treatments. Dr. Schmidt highlights the shift from limited options to a wide array of choices, emphasizing patient convenience as a key factor in treatment selection. She discusses alternative delivery models like nadofaragene firadenovec, and combination therapies pairing intravesical and s...
|
- Details
- Ashish Kamat is joined by Jens Bedke to discuss BCG treatment and the global shortage in bladder cancer care. Professor Bedke shares insights from a study of 1,900 high-risk non-muscle invasive bladder carcinoma patients, revealing that only two-thirds received the recommended BCG therapy. He discusses significant regional differences in BCG availability, with Germany having better access compared...
|
- Details
- Siamak Daneshmand and Alireza Ghoreifi join Ashish Kamat to discuss data from the blue light cystoscopy registry. Their analysis of 2,854 patients who underwent TURBT with blue light cystoscopy reveals that 9.3% experienced risk group migration, with 6% moving to high risk, 2.1% to intermediate risk, and 1.2% from no findings to low risk. The discovery of carcinoma in situ serves as the primary dr...
|
- Details
- Muhammad Hassan Alkazemi and Hikmat Al-Ahmadie speak with Ashish Kamat about a retrospective analysis of micropapillary urothelial carcinoma. The study compares 130 micropapillary cases to 430 conventional urothelial carcinoma patients who underwent radical cystectomy at Memorial Sloan Kettering. Results demonstrate significantly worse overall survival for micropapillary cases (37 months versus 84...
|
- Details
- Vikram Narayan discusses detalimogene voraplasmid (EG-70), a non-viral therapy for bladder cancer that uses a proprietary delivery mechanism to introduce DNA plasmid into the bladder. EG-70 employs a dual approach by activating both the innate immune system through RIG-1 agonists and the adaptive immune system via IL-12 secretion. Preclinical studies demonstrate T-cell recruitment, tumor microenvi...
|
